Exicure, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
XCUR Nasdaq 2830 www.exicuretx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Exicure, Inc.

Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting - Dec 8th, 2025 2:30 pm
Exicure, Inc. Reports Third Quarter 2025 Financial Results - Nov 7th, 2025 2:00 pm
New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting - Nov 3rd, 2025 7:00 am
Exicure Highlights Recent Achievements and Near-term Strategic Priorities - Oct 6th, 2025 5:00 am
Exicure, Inc. Reports Second Quarter 2025 Financial Results - Aug 8th, 2025 2:01 pm
Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements - Aug 4th, 2025 2:37 pm
Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant - Aug 1st, 2025 2:01 pm
Exicure, Inc. Reports First Quarter 2025 Financial Results - Jun 27th, 2025 2:01 pm
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q - May 28th, 2025 2:58 pm
Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant - May 5th, 2025 6:00 am
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma - Apr 14th, 2025 4:11 pm
Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML) - Apr 11th, 2025 5:42 pm
Exicure, Inc. Reports Full Year 2024 Financial Results - Mar 18th, 2025 2:01 pm
Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia - Mar 13th, 2025 2:08 pm
CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc. - Jan 22nd, 2025 10:17 pm
Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech - Dec 26th, 2024 6:08 pm
CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes - Dec 21st, 2024 11:48 am